Short-Term Debt to Equity Ratio: Reviva Pharmaceuticals (RVPH)
Reviva Pharmaceuticals collaborates with research centers to develop advanced antipsychotics, conducting tests for psoriasis and schizophrenia therapies. Anticipation of the primary drug's approval following Phase 3 trials serves as a driver, while safety costs are already priced in, and the indicator stands at 0.05. The business relies on the development of Brilaroxazine, which treats bipolar disorders without side effects such as tremors or weight gain. The price history on the chart below clearly illustrates the price action of RVPH.
Financial and market metric breakdowns for revivapharma.com (RVPH)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Reviva Pharmaceuticals|RVPH - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Reviva Pharmaceuticals Holdings, Inc.|RVPH - Company Cumulative Debt|Debt to Book Value Reviva Pharmaceuticals Holdings Inc.|RVPH - Company Long-Term Debt|Company Short-Term Debts Reviva Pharmaceuticals|Quick Liquidity Indicator revivapharma.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:Reviva Pharmaceuticals Holdings RVPH
For the biotech sector, Reviva Pharmaceuticals (RVPH) finds it critically important to maintain liquidity while developing costly neuropsychiatric drugs. By analyzing the ratio of short-term debt to equity, an investor assesses the share of liabilities due within one year relative to net assets, which determines the company's resilience to interest rates. Low dependence on short-term loans confirms the reliability of the foundation established by patents and guarantees a stable path toward future cash flows.
Competing companies
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|DNLI: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital HRMY|BHVN - Current Liabilities to Capital|Amylyx - Short-Term Debt to Equity Ratio|Trevi Corp - Short-Term Debt to Equity|Praxis Precision Medicines - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient anavex.com AVXL|CBLL (CeriBell) - Short-Term Debt to Equity Ratio|PRTA (Prothena Biosciences) - Short-Term Debt to Equity|ALEC (Alector Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Annexon Biosciences Inc.|Short-Term Debt to Equity Ratio OMER (Omeros Corporation)|NGNE (neurogene.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity AC Immune SA ACIU|VYGR (Voyager Therapeutics Inc) - Current Liabilities to Equity|Neumora Therapeutics Inc - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital SCLX (Scilex Holding Company, Inc.)|TVGN: Short-Term Debt to Capital|Alpha Cognition Inc. (ACOG) - Short-Term Debt to Capital|Short-Term Debt to Equity Cognition Therapeutics, Inc.|IKT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Cassava (SAVA)|Short-Term Debt to Equity Ratio assertiotx.com ASRT|Short-Term Debt to Capital COYA (Coya Therapeutics)|Short-Term Debt to Capital VistaGen Therapeutics, Inc. VTGN|Ovid Rx - Short-Term Debt to Capital|Acumen Pharmaceuticals Inc. (ABOS) - Short-Term Debt to Equity Ratio|CRVO: Short-Term Debt to Capital|Current Liabilities to Capital Alterity Therapeutics Limited (ATHE)|Short-Term Debt to Equity Ratio CLNN|Short-Term Debt to Capital PepGen Corp|Short-Term Debt to Equity Ratio JUNS (Jupiter Neurosciences)|Short-Term Loans to Capital Ratio RLMD|Short-Term Debt to Capital ANVS (Annovis Bio Corp)|Short-Term Debt to Capital Coefficient Grace Therapeutics Inc (GRCE)|Firefly Neuroscience, Inc - Short-Term Debt to Capital|Klotho Neurosciences Inc (KLTO) - Short-Term Debt to Equity Ratio|NRSN: Short-Term Debt to Capital|MetaVia (MTVA) - Short-Term Debt to Capital|Short-Term Debt to Equity NeurAxis, Inc|Short-Term Debt to Equity HSDT|Short-Term Debt to Equity Passage Bio, Inc. (PASG)|Short-Term Debt to Capital Coefficient bionomics.com.au|Short-Term Debt to Equity Minerva Neurosciences, Inc. NERV|Ratio of Short-Term Indebtedness to Capital ATHA|ADXN: Short-Term Debt to Equity Ratio|ALZN: Short-Term Debt to Equity|cyclerion.com (CYCN) - Short-Term Debt to Equity|Current Liabilities to Equity PTIX (Protagenic Therapeutics, Inc.)|KTTA (Pasithea Therapeutics Corp) - Short-Term Debt to Capital|CRGT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BrainStorm Cell Therapeutics Inc. - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital CARA (Cara Therapeutics, Inc.)|chromocell.com (CHRO) - Current Liabilities to Capital|ELYM: Short-Term Debt to Equity Ratio|ITCI - Short-Term Debt to Capital|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Marinus Pharma - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Equity Sage Therapeutics (SAGE)|SNPX (Synaptogenix Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital TRVN (Trevena, Inc)|Vigil Neuroscience Inc. (VIGL) - Current Liabilities to Capital|WENA: Short-Term Debt to Equity Ratio|CERE: Short-Term Debt to Equity